Skip to main content

Antitrust, Commercial, and Administrative Law

November 17, 2016
Washington, D.C.— House Judiciary Committee Chairman Bob Goodlatte (R-Va.), Regulatory Reform, Commercial, and Antitrust Law Subcommittee Chairman Tom Marino (R-Pa.), and Courts, Intellectual Property, and the Internet Subcommittee Chairman, and sponsor of the bill, Darrell Issa (R-Calif.), issued the following statements upon the House’s passage of the Midnight Rules Relief Act (H.R.
November 17, 2016
https://www.youtube.com/watch?v=SWasV3pf4is Chairman Goodlatte: As the Obama Administration comes to a close, Americans’ freedom and prosperity is once again threatened by one of the most abusive features of modern bureaucracy—“Midnight Regulation.” “Midnight regulation” is one of the most vexing problems in Washington’s overreaching regulatory system.  Administration after administration, there is a spike in rulemaking activity during the last year of a president’s term—particularly between Election Day and Inauguration Day, but even in the months before then. Th
September 27, 2016

*This hearing is postponed until a date and time TBD*

Washington, D.C. — On Thursday, September 29, 2016, at 10:00 a.m., the Subcommittee on Regulatory Reform, Commercial and Antitrust Law will hold an oversight hearing to examine the activities of four Department of Justice (DOJ) components (Civil; Tax; Environment and Natural Resources; an

September 23, 2016
Washington, D.C. – The House Judiciary Committee has announced its schedule for the week of September 26-30, 2016. TUESDAY, SEPTEMBER 2710:00 a.m. | Subcommittee on Immigration and Border Security Hearing on: New Orleans: How the Crescent City Became a Sanctuary City Witnesses:
  • The Honorable Jeff Landry, Attorney General, Louisiana Department of Justice
  • The Honor
September 22, 2016
Chairman Goodlatte: Today’s proceeding marks the fourth in our series of hearings focused on competition in the health care marketplace.  Now, the Committee turns its attention to the pharmaceutical industry and the drugs that are used in the treatment of opioid overdose and addiction. Competition in the addiction medicine markets, like the pharmaceutical market as a whole, involves a delicate balance.  On the one hand, we want to encourage pharmaceutical companies to invest in expensive research and development in order to bring innovative and life-saving drug
September 21, 2016
Washington, D.C.—Today House Judiciary Committee Chairman Bob Goodlatte (R-Va.) and the bill’s sponsor Rep. Mike Bishop (R-Mich.) issued the following statements upon the passage of the Mobile Workforce State Income Tax Simplification Act of 2015 (H.R.
September 21, 2016
Chairman Goodlatte: The Mobile Workforce State Income Tax Simplification Act provides a clear, uniform framework for when States may tax nonresident employees who travel to the taxing State to perform work. In particular, this bill prevents States from imposing income tax compliance burdens on nonresidents who work in a foreign State for fewer than 30 days in a year. The State tax laws that determine when a nonresident must pay a foreign State's income tax and when employers must withhold this tax are numerous and varied. Some States tax income earned wit
September 21, 2016
Washington, D.C. —House Judiciary Committee Chairman Bob Goodlatte (R-Va.) and Regulatory Reform, Commercial and Antitrust Law Subcommittee Chairman Tom Marino (R-Pa.) issued the following statements on today’s approval by the House of Representatives of the “Require Evaluation before Implementing Executive Wishlists (REVIEW) Act of 2016” (H.R.
September 21, 2016
Chairman Goodlatte: Washington’s regulatory system one that virtually every day places new obstacles in the path of American jobs and economic growth. The biggest obstacles of all are new regulations that impose more than $1 billion per year in costs on the American economy. Struggling workers, families and small business owners have every right to ask why regulations that cost this much are ever promulgated at all.  Surely there are less costly measures that are effective and should be adopted instead.